Literature DB >> 14644934

What do we gain from the sixth coronary heart disease drug?

Rebecca N Warburton.   

Abstract

Entities:  

Mesh:

Year:  2003        PMID: 14644934      PMCID: PMC286232          DOI: 10.1136/bmj.327.7426.1237

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  7 in total

1.  What do we gain from the sixth stool guaiac?

Authors:  D Neuhauser; A M Lewicki
Journal:  N Engl J Med       Date:  1975-07-31       Impact factor: 91.245

2.  The use of statins: a case of misleading priorities?

Authors:  N Freemantle; R Barbour; R Johnson; M Marchment; A Kennedy
Journal:  BMJ       Date:  1997-10-04

Review 3.  Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.

Authors:  G J Hankey; C L Sudlow; D W Dunbabin
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 4.  Universal precautions to prevent HIV transmission to health care workers: an economic analysis.

Authors:  S R Stock; A Gafni; R F Bloch
Journal:  CMAJ       Date:  1990-05-01       Impact factor: 8.262

5.  Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.

Authors:  Jean-Michel Gaspoz; Pamela G Coxson; Paula A Goldman; Lawrence W Williams; Karen M Kuntz; M G Myriam Hunink; Lee Goldman
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

6.  Coronary heart disease prevention: insights from modelling incremental cost effectiveness.

Authors:  Tom Marshall
Journal:  BMJ       Date:  2003-11-29

7.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

  7 in total
  4 in total

1.  Prevention of coronary heart disease: is a cure too expensive?

Authors:  G Alastair Cooke
Journal:  BMJ       Date:  2004-02-14

2.  [Primary prevention of coronary heart disease? What is cost effective in the clinical practice?].

Authors:  W Kübler
Journal:  Z Kardiol       Date:  2005

3.  Improving secondary prevention in coronary bypass patients: closing the audit loop.

Authors:  T N Martin; R J Irving; M Sutherland; K Sutherland; P Bloomfield
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

4.  Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999).

Authors:  Aukje K Mantel-Teeuwisse; Olaf H Klungel; Albert Hofman; W M Monique Verschuren; Paul H Trienekens; Arijan J Porsius; Bruno H Ch Stricker; Anthonius de Boer
Journal:  Br J Clin Pharmacol       Date:  2006-05       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.